Equities analysts expect Horizon Pharma PLC (NASDAQ:HZNP) to post earnings of $0.22 per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Horizon Pharma’s earnings, with the lowest EPS estimate coming in at $0.19 and the highest estimate coming in at $0.24. Horizon Pharma reported earnings of $0.66 per share during the same quarter last year, which suggests a negative year over year growth rate of 66.7%. The business is scheduled to report its next earnings results before the market opens on Wednesday, February 28th.
On average, analysts expect that Horizon Pharma will report full year earnings of $1.09 per share for the current financial year, with EPS estimates ranging from $1.04 to $1.13. For the next fiscal year, analysts forecast that the company will report earnings of $1.30 per share, with EPS estimates ranging from $1.04 to $1.42. Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Horizon Pharma.
Several research analysts have recently commented on the company. Cantor Fitzgerald set a $17.00 target price on Horizon Pharma and gave the stock a “buy” rating in a research note on Monday, January 8th. UBS Group set a $20.00 target price on Horizon Pharma and gave the stock a “buy” rating in a research note on Thursday, November 30th. ValuEngine cut Horizon Pharma from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. BidaskClub raised Horizon Pharma from a “hold” rating to a “buy” rating in a report on Friday, December 22nd. Finally, Jefferies Group lifted their price target on Horizon Pharma from $16.00 to $21.00 and gave the stock a “buy” rating in a report on Tuesday, November 7th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and eleven have issued a buy rating to the stock. Horizon Pharma has an average rating of “Buy” and a consensus price target of $19.25.
A number of large investors have recently added to or reduced their stakes in the stock. Sei Investments Co. boosted its stake in Horizon Pharma by 68.5% in the third quarter. Sei Investments Co. now owns 391,170 shares of the biopharmaceutical company’s stock valued at $4,961,000 after acquiring an additional 159,002 shares in the last quarter. Canada Pension Plan Investment Board boosted its stake in Horizon Pharma by 348.9% in the third quarter. Canada Pension Plan Investment Board now owns 101,900 shares of the biopharmaceutical company’s stock valued at $1,292,000 after acquiring an additional 79,200 shares in the last quarter. American International Group Inc. boosted its stake in Horizon Pharma by 8.1% in the third quarter. American International Group Inc. now owns 109,477 shares of the biopharmaceutical company’s stock valued at $1,388,000 after acquiring an additional 8,185 shares in the last quarter. Wells Fargo & Company MN boosted its stake in Horizon Pharma by 24.8% in the third quarter. Wells Fargo & Company MN now owns 456,169 shares of the biopharmaceutical company’s stock valued at $5,784,000 after acquiring an additional 90,692 shares in the last quarter. Finally, Chicago Equity Partners LLC acquired a new stake in Horizon Pharma in the third quarter valued at approximately $1,726,000. 84.39% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This article was posted by Week Herald and is the sole property of of Week Herald. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://weekherald.com/2018/03/14/zacks-analysts-expect-horizon-pharma-plc-hznp-will-post-earnings-of-0-22-per-share.html.
About Horizon Pharma
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.